Rimonabant online. Best prices from TOP pharmacies.

People who take the weight-loss drug rimonabant may face heightened risks for severe depression and anxiety, Danish researchers report.
The finding follows a recommendation by a U.S. Food and Drug Administration panel in June…

Abstract
Introduction: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes.
Aims: To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overw…

MUNICH — The investigational drug rimonabant, first in a new class of agents known as selective endocannabinoid type 1 receptor blockers, is looking more and more like the real deal: a potential blockbuster drug causing sustained weight loss in the obese, reversal of t…

SAN DIEGO — The investigational drug rimonabant produces highly significant cardiovascular and metabolic benefit in patients with type 2 diabetes, Andre Scheen, M.D., reported at the annual scientific sessions of the American Diabetes Association.
Earlier this year, Sanofi-Aventis filed for U.S. and European licensure of the selective endocannabinoid type 1–receptor blocker, based on data from a series of phase III trials involving more t…

New data on rimonabant suggest that the selective endocannabinoid type 1-receptor blocker has beneficial effects on glycemic control and other risk factors in diabetic patients.
In treatment-naive patients with type 2 diabetes, 6 months of rimonabant t…

Sanofi-aventis has withdrawn its application to sell rimonabant, an antiobesity drug. The decision came after a Food and Drug Administration panel recommended that the agency not approve the drug because of concerns that its use could lead to depression and suicidal thinking.

Related Results

Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular r…

Rimonabant, an investigational drug that is a cannabinoid-1 receptor blocker, promoted modest but sustained decreases in weight and waist circumference when combined with a low-calorie diet, reported Dr. F. Xavier Pi-Sunyer of the Obesity Research Center at St. Luke’s-Roosevelt Hospital, New …

Mice given the weight-loss drug rimonabant became resistant to alcohol’s fat-building effects in the liver, which suggests the medication may help fight alcoholic fatty liver in humans, says a U.S. study.
Alcoholism is the leading cause of liver disease in Western societies, according to background information in the study.
Rimonabant, which blocks cannabinoid receptors, is approved for weight loss in several European countries but ha…

New findings reported at the American Heart Association Scientific Sessions in New Orleans, Louisiana, show that first-year improvements in cardiovascular risk factors seen in obese patients treated with Sanofi-Aventis’ Acomplia (rimonabant) are sustained in the second year of therapy.

Related Re…

Monster can be defeated only with the help of proper weapon. Obesity is a dangerous monster which is devouring people’s health and their lives. The devil never comes alone; then how can obesity come alone? High blood pressure, high blood sugar, kidney failure, heart attack, arthritis are the killers…